Genetic lesions, namely, the IDH1/2 mutation (IDH-mut, for glossary, see Abbreviations) in combination with co-deletions of chromosomes 1 and 19 (Chr.1p19q codel) presently provide the major outcome- and treatment-relevant molecular glioma markers [1,2]. The gene discussed is IDH1; the disease is central nervous system cancer.